(Total Views: 390)
Posted On: 05/15/2025 7:10:39 AM
Post# of 154875
I don't use AI very often, but I asked ChatGPT:
"Has Cytodyn news come out of ESMO Munich?" This is the response:
"
Yes, CytoDyn has announced plans to present data at the European Society for Medical Oncology (ESMO) Congress in Munich, Germany, in May 2025. In its March 2025 Letter to Shareholders, the company revealed that it submitted an abstract detailing survival outcomes in patients with metastatic triple-negative breast cancer (mTNBC) who were treated with leronlimab in prior CytoDyn-sponsored studies. The data indicate increased survival rates at 12, 24, and 36 months, suggesting that leronlimab could play a significant role as a paradigm-shifting therapeutic in oncology. CytoDyn is eager to share additional insights into the apparent mechanism behind these survival outcomes at the ESMO meeting, in compliance with pre-conference publication and announcement allowances.
CytoDyn Inc.+3CytoDyn Inc.+3CytoDyn Inc.+3
As of now, there have been no public updates or press releases confirming whether the abstract has been accepted or if the data will be presented at the conference. The company has indicated that it will provide updates in the coming months as they become available. Therefore, it is advisable to monitor CytoDyn’s official press releases and the ESMO 2025 conference program for the latest information.
Is this accurate?
"Has Cytodyn news come out of ESMO Munich?" This is the response:
"
Yes, CytoDyn has announced plans to present data at the European Society for Medical Oncology (ESMO) Congress in Munich, Germany, in May 2025. In its March 2025 Letter to Shareholders, the company revealed that it submitted an abstract detailing survival outcomes in patients with metastatic triple-negative breast cancer (mTNBC) who were treated with leronlimab in prior CytoDyn-sponsored studies. The data indicate increased survival rates at 12, 24, and 36 months, suggesting that leronlimab could play a significant role as a paradigm-shifting therapeutic in oncology. CytoDyn is eager to share additional insights into the apparent mechanism behind these survival outcomes at the ESMO meeting, in compliance with pre-conference publication and announcement allowances.
CytoDyn Inc.+3CytoDyn Inc.+3CytoDyn Inc.+3
As of now, there have been no public updates or press releases confirming whether the abstract has been accepted or if the data will be presented at the conference. The company has indicated that it will provide updates in the coming months as they become available. Therefore, it is advisable to monitor CytoDyn’s official press releases and the ESMO 2025 conference program for the latest information.
Is this accurate?
(0)
(0)
